Abstract Emerging evidence suggests that CNS injury and neurocognitive impairment persist in the setting of chronic HIV infection and combination antiretroviral therapy (CART). Yet, whether neurological injury can progress in this setting remains uncertain. Magnetic resonance spectroscopy and neurocognitive and clinical assessments were performed over 2 years in 226 HIV-infected individuals on stable CART, including 138 individuals who were neurocognitively asymptomatic (NA). Concentrations of N-acetylaspartate (NAA), creatine (Cr), choline (Cho), myoinositol, and glutamate/glutamine (Glx) were measured in the midfrontal cortex (MFC), frontal white matter (FWM), and basal ganglia (BG). Longitudinal changes in metabolite levels were determined using linear mixed effect models, as were metabolite changes in relation to global neurocognitive function. HIV-infected subjects showed significant annual decreases in brain metabolite levels in all regions examined, including NAA (2.95 %) and Cho (2.61 %) in the FWM; Neurovirol. (2013) 19:209-218 DOI 10.1007 NAA (1.89 %), Cr (1.84 %), Cho (2.19 %), and Glx (6.05 %) in the MFC; and Glx (2.80 %) in the BG. Similar metabolite decreases were observed in the NA and subclinically impaired subgroups, including subjects with virologic suppression in plasma and CSF. Neurocognitive decline was associated with longitudinal decreases in Glx in the FWM and the BG, and in NAA in the BG. Widespread progressive changes in the brain, including neuronal injury, occur in chronically HIV-infected persons despite stable antiretroviral treatment and virologic suppression and can lead to neurocognitive declines. The basis for these findings is poorly understood and warrants further study.
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Background
The successful suppression of HIV infection afforded by combination antiretroviral therapy (CART) has led to a significant decrease in systemic as well as brain complications, including neurocognitive and functional impairment, commonly referred to as AIDS dementia complex (ADC) or HIV-associated neurocognitive disorder (HAND) (Antinori et al. 2007; Hammer et al. 2006; Navia et al. 1986a, b; Palella et al. 1998; Robertson et al. 2007; Sacktor et al. 2002) . Although dementia has become relatively rare in settings with ready access to CART, milder forms of HAND remain common, with nearly 50 % of chronically treated people showing neurocognitive impairment, comparable to rates reported pre-CART (Heaton et al. 2010 (Heaton et al. , 2011 Tozzi et al. 2007 ). Furthermore, increasing evidence largely drawn from neuroimaging studies suggests that brain pathology persists in CART-treated individuals (Cardenas et al. 2009; Cohen et al. 2010a, b; Harezlak et al. 2011; Thompson et al. 2005) . Nonetheless, it remains unclear whether brain injury can further progress in the setting of stable disease and treatment, particularly among neurocognitively asymptomatic individuals.
Proton magnetic resonance spectroscopy (MRS) provides a sensitive noninvasive method to measure specific cerebral metabolites that reflect neuronal and glial dysfunction and neuroinflammation. Numerous cross-sectional studies in HIV-infected persons and in an SIV macaque model have described a consistent pattern of metabolite abnormalities in both gray and white matter brain regions, particularly in the frontal white matter and basal ganglia, comprising of alterations in N-acetylaspartate (NAA), a marker of neuronal metabolism, and choline-containing compounds (Cho) and myoinositol (MI), markers of cell membrane damage and glial cell activity (Chang et al. 2004; Harezlak et al. 2011; Lentz et al. 2009; Lopez-Villegas et al. 1997; Meyerhoff et al. 1999; Mohamed et al. 2010; Paul et al. 2007; Tracey et al. 1996 Tracey et al. , 1997 Urenjak et al. 1993; Yiannoutsos et al. 2004) . Metabolite abnormalities have also been associated with disease history, neurocognitive function, and volumetric brain abnormalities (Chang et al. 2004; Cohen et al. 2010a; Harezlak et al. 2011; Mohamed et al. 2010; Paul et al. 2007; Yiannoutsos et al. 2004) .
Despite considerable evidence of HIV-associated brain disease, there have been no published longitudinal studies to date of metabolite abnormalities in the setting of chronic infection and treatment. The HIV Neuroimaging Consortium was formed to examine such changes in a prospective multicenter cohort of chronically HIV-infected individuals with history of advanced disease (nadir CD4<200 cells/ml) on stable CART. In a recent cross-sectional MRS study of 240 HIV-infected individuals, we reported significant elevations in Cho and MI in all groups, while decreased NAA levels were observed only among those with neurocognitive impairment (Harezlak et al. 2011) . The current prospective MRS and neurocognitive study was performed in 226 of these individuals, including 138 neurocognitively asymptomatic individuals, over 2 years. We hypothesized that, despite stable antiretroviral treatment, such individuals will show progressive changes in cerebral metabolite levels, even in the setting of virologic suppression. In addition, we hypothesized that such changes will be associated with neurocognitive decline.
Methods

Participants
Participants included 226 HIV-infected individuals who were enrolled in a longitudinal study of HIV-associated brain injury at the following sites: University of California San Diego, University of California Los Angeles (UCLA), Harbor-UCLA Medical Center, Stanford University, University of Colorado, University of Pittsburgh, and Rochester University. Demographic and clinical characteristics are shown in Table 1 . All participants gave written informed consent, and institutional review boards at each site approved the protocol. Inclusion criteria included: nadir CD4 level<200 cells/ml; stable FDA-approved antiretroviral regimen ≥ 12 consecutive weeks; hemoglobin > 9.0 g/dl; serum creatinine ≤ 3× upper limit of normal (ULN); AST (SGOT), ALT (SGPT), and alkaline phosphatase≤3×ULN. Exclusion criteria included: neurologic conditions including seizure disorder, stroke, head trauma with loss of consciousness>30 min, multiple sclerosis, brain infection apart from HIV, and brain neoplasms; history of severe psychiatric disorders; active alcohol and substance abuse within 6 months of study; and diabetes mellitus with a fasting glucose>140 mg/dl.
Clinical assessments
Participants underwent repeated neuroimaging, neurological, and neuropsychological assessments as previously described (Harezlak et al. 2011) . Neuropsychological evaluation was performed in cognitive domains most implicated in HIV infection, including processing speed, verbal fluency, executive functioning, working memory, learning and memory, and psychomotor function (Heaton et al. 1995) . Individual tests in each cognitive domain are listed in Table 2 . The most updated demographically corrected norms for each test were used to convert individual test scores into standard scores (T scores, mean=50, SD=10). A previously validated algorithm was used to derive a global deficit score (GDS) for each participant reflecting the overall degree of cognitive impairment. Specifically, the demographically corrected T scores on individual neuropsychological measures were converted to deficit scores ranging from 0 (no impairment) to 5 (severe impairment). The GDS was then derived by averaging the deficit scores for all measures. Previous studies have demonstrated the utility of the GDS in detecting cognitive impairment in HIV-infected individuals (Carey et al. 2004; Heaton et al. 1995) .
ADC staging was performed by a trained clinician at each site and was based on the neurological examination, assessment of functional impairment, and neuropsychological performance as previously described (Harezlak et al. 2011) . Subsequent to the inception of this study, a new nosologic classification for HAND was proposed, with ADC stage 0 (asymptomatic) corresponding to neurocognitively normal, stage 0.5 (subclinical) to asymptomatic neurocognitive impairment, stage 1 (symptomatic) corresponding to mild neurocognitive disorder, and stage 2 or greater to HIV-associated dementia (Antinori et al. 2007 ).
MRS acquisition and processing
1 H MRS spectra were acquired with 1.5-T General Electric magnetic resonance systems (GE Healthcare, Waukesha, WI) at seven participating sites using the GE quadrature head coil and the manufacturer's PRESS sequence. Field homogeneity and water suppression were adjusted using automated algorithms from GE. Water-suppressed spectra were collected with Values reported as median (Q1, Q3) unless noted otherwise. No significant group differences were found in any of the variables (p>0.05)
CART combination antiretroviral therapy a CSF viral load data were available for 82 participants Table 2 Neuropsychological tests administered as part of this study organized by cognitive domains. Details of the individual tests have been described elsewhere (Heaton et al. 1995; Rippeth et al. 2004) Cognitive TE/TR=35/3,000 ms, bandwidth=2,500 Hz, 128 averages. In addition, a customized pulse program was run to automatically collect single-scan, fully relaxed water free induction decays (FIDs) from each voxel at seven different echo times (TE=35, 45, 65,100, 200, 500, and 1,500 ms; TR=15 s). From this, voxel partial volumes were determined to correct absolute metabolite concentrations Kreis et al. 1993) . Regions of interest (ROI) 6 cc in volume were prescribed in the midfrontal cortical gray matter located in the anterior cingulate (midfrontal cortex, MFC), frontal white matter located in the centrum semiovale (frontal white matter, FWM), and basal ganglia (BG). Laterality of the FWM and BG ROIs were alternated between participants but maintained for repeat studies for each participant. For quality control, sites were required to acquire a phantom spectrum within 24 h of each in vivo scan, using the identical MRS protocol as described above. The quality of the MR spectra and voxel locations was monitored continuously at the University of Hawaii, based on visual inspection and outputs from the LCModel spectral analysis software (Provencher 2001) , with unsuppressed water FID at TE= 35 ms used for eddy-current correction. The percent SD (estimated standard deviations as percent of the estimated concentrations) and full width at half maximum (FWHM, an estimate of peak width) were used to determine spectrum quality. Percent SD of less than 20 and FWHM of less than 0.1 ppm constitute a reliable estimate for a particular metabolite. Both absolute concentration and metabolite/creatine (Cr) ratio were computed for NAA, MI, Cho, glutamate + glutamine (Glx), and Cr. The coefficient of variation of the metabolite estimates was <15 %. Analysis of the phantom data from the current study showed that the variability in measurements of metabolite ratios was smaller than the variability in the study population, consistent with our reported findings in an independent cohort (Lee et al. 2003) . The variability in the phantom metabolite ratio between the seven sites did not exceed 7 % from the overall mean with most of the variations falling within 2-3 %. Longitudinal analysis of phantom measurements taken at all sites also showed limited variability in metabolite concentrations over time.
Statistical analysis
Longitudinal analyses were performed using linear mixed effect models with length of time since enrollment as an independent covariate and participant-specific random intercepts and slopes (Laird and Ware 1982) . The annual rates of change and their associated standard errors were estimated based on the regression coefficients corresponding to the mean metabolite levels at baseline and the change in their concentrations over the 2-year time period. Additional longitudinal analyses were done for participants with undetectable plasma HIV RNA (N = 184) as well as undetectable CSF HIV RNA at baseline (N=51). In addition, we determined the rates of change for each clinical group defined by baseline ADC stages 0, 0.5, and 1+ (see "Clinical assessments" section above). To determine disease stability, the longitudinal change in CD4 count and the proportion of subjects with detectable plasma HIV RNA levels were assessed by linear and generalized linear mixed models, respectively. Linear mixed methods analyses were also used to determine the relationships between the rates of changes in metabolite levels and changes in global neurocognitive function. First, we predicted the participantspecific rates of both metabolite change and neurocognitive change using individual random intercepts and slopes. Then, Pearson's product moment correlations were estimated between the individual predicted metabolite rates and neurocognitive score rates, and tested for the difference of these correlations from zero using Fisher's Z transform.
Results
Cohort
Median age of participants was 47 years, while median duration of HIV infection was 11 years at baseline. All participants had history of advanced immunosuppression (median nadir CD4= 37 cells/ml), but a median current CD4 level of 326, consistent with successful immunological restoration in response to antiretroviral therapies. The majority of participants were maintained on the same CART regimen for at least 1.5 years, with 81 % showing undetectable plasma HIV RNA levels. CSF HIV RNA levels were available for 82 participants, of which 60 (73 %) were undetectable; while both plasma and CSF HIV RNA were undetectable in 51 participants (62 %). Longitudinal analyses examining HIV disease stability during the study showed that mean CD4 levels increased by 6.9 % over 2 years, while the percentage of patients with undetectable plasma RNA remained stable at around 80 %.
Longitudinal metabolite changes in the whole cohort Significant decreases in absolute concentrations were observed in all brain regions examined (Table 3 ). The FWM showed significant annual decreases in NAA (2.95 %, p< 0.0001) and Cho (2.61 %, p = 0.0001). The MFC also showed significant decreases in NAA (1.89 %, p=0.0007), Cr (1.84 %, p=0.0059), Cho (2.19 %, p=0.0123, and Glx (6.05 %, p<0.0001) (Fig. 1) . A marginal decrease in MI was found in the MFC (1.81 %, p=0.0578). The BG showed a significant decrease in only Glx (2.80 %, p=0.0043). Analyses of metabolite/Cr ratios showed similar patterns of change in fewer brain regions. Significant decreases in NAA/Cr (2.51 %, p<0.0001) and Cho/Cr (1.74 %, p= 0.0123) were observed in the FWM, while the MFC showed decreases in Glx/Cr (3.84 %, p<0.0001). No significant changes in metabolite/Cr ratios in the BG were found. Table 4 shows estimated annual changes in all measured absolute metabolite concentrations and metabolite/Cr ratios in the three brain regions.
The estimated rates of change in the phantom metabolite levels were much smaller than those found in the study cohort. Specifically, the rates of change in absolute concentrations were −1.10 % for NAA, −0.93 % for Cr, and −1.18 % for Cho, while rates of change observed in the study cohort were between 1.7 and 2.7 times larger in magnitude for metabolites showing significant changes. Similarly, the rates of change in the relative concentrations were −0.37 % for NAA/Cr and −0.63 % for Cho/Cr ratio. Again, the significant changes in the metabolite ratios were between 2.8 and 6.8 times larger in magnitude in the cohort.
Longitudinal changes by neurocognitive status
To examine whether metabolite changes differed with neurocognitive status, longitudinal analyses of metabolite levels were performed in subgroups stratified according to ADC stage (Table 4) . Overall, neurocognitively asymptomatic (NA) (ADC 0) and subclinically impaired (ADC 0.5) subjects showed similar patterns of metabolite changes, including significant decreases in NAA and Cho in the FWM, and decrease in Glx in the MFC. In addition, NA subjects showed significant decreases in NAA and Cr in the MFC, while participants in the subclinical group showed significant decreases in Cho in the MFC and Glx in the BG. Symptomatic subjects (ADC stage ≥1 showed relatively fewer metabolite changes, including significant decreases in Glx in the MFC, in addition to decreases in Cr and Cho in the BG.
Longitudinal changes in participants with undetectable HIV RNA To further examine whether significant metabolite changes occurred even in virologically suppressed individuals, we examined longitudinal metabolite changes in a subgroup of subjects with undetectable plasma HIV RNA at baseline (N=184) and another subgroup with undetectable HIV RNA in both plasma and CSF (N=51) ( Table 4) . Participants with plasma virologic suppression showed similar patterns of metabolite changes as in the whole cohort. In participants with virologic suppression in both plasma and CSF (N=51), significant decreases were found in NAA in the FWM, Glx, and MI in the MFC, and NAA in the BG.
Changes in metabolite levels relative to cognitive decline
We assessed whether changes in metabolite levels were associated with changes in global cognitive function. Increase in the GDS score (reflecting cognitive decline) was significantly associated with decreases in Glx/Cr in the FWM (p=0.0319) and Glx/Cr in the BG (p=0.0468). A marginal relationship was found between increased GDS and decreased absolute NAA level in the BG (p=0.0568).
Discussion
Whether chronically HIV-infected individuals can develop progressive brain abnormalities despite successful viral suppression and immunological restoration in response to antiretroviral treatment has remained an important yet unresolved question. In this prospective study, we found significant annual decreases ranging from 2 to 6 % in the levels of several metabolites, notably NAA and Glx, markers of neuronal and glial cell function, in both cortical and subcortical brain regions. The current results are remarkable in that progressive metabolite changes were observed even among neuroasymptomatic individuals with virologic suppression. Together, these findings suggest that HIVassociated bran injury can progress in the absence of overt symptoms and that effective antiretroviral treatment may not be sufficient to prevent this complication.
There have been few MRS prospective studies reported (Kantarci et al. 2007; Olson et al. 2008; Pilatus et al. 2009; Schott et al. 2010) . Metabolite levels in healthy controls NAA N-acetylaspartate, Cho choline-containing compounds, Glx glutamate + glutamine, Cr creatine, FWM frontal white matter, MFC midfrontal cortical gray matter, BG basal ganglia a CSF viral load data were available for 82 participants acquired using similar methods as described here remain relatively unchanged over time compared to those observed in the study patient. In this study, longitudinal phantom measurements were acquired with each imaging session to assess whether changes observed in the HIV subjects could be attributed to scanner drift or measurement instability. The findings were consistent with those reported in previous studies among healthy adults and argue strongly that the observed changes were due to biological rather than scanner-related factors. The current findings expand on a large body of crosssectional evidence showing the association between HIV infection and various patterns of brain injury as measured by MRS (Chang et al. 2004; Lopez-Villegas et al. 1997; Meyerhoff et al. 1999; Mohamed et al. 2010; Paul et al. 2007; Tracey et al. 1996; Urenjak et al. 1993; Yiannoutsos et al. 2004) . Observed abnormalities have consistently included elevated levels of the inflammatory markers Cho and MI among HIV-infected individuals regardless of cognitive status whereas decrease in NAA, a marker of neuronal integrity, has consistently been observed in individuals with neurocognitive impairment (NCI), suggesting that neural dysfunction may be necessary in its expression (Chang et al. 2004; Harezlak et al. 2011; Mohamed et al. 2010; Paul et al. 2007; Yiannoutsos et al. 2004 ). It is of interest then that, in the setting of chronic infection and treatment, progressive decreases in NAA both in gray and white matter were observed in NA subjects suggesting these individuals may be at risk for developing NCI. In contrast, symptomatic subjects (ADC>1), although showing similar patterns of change, had more extensive involvement of the basal ganglia, consistent with earlier observations that injury to this region is a critical event leading to symptomatic impairment (Brew et al. 1995; Navia et al. 1986a; Rostasy et al. 1999) . Further, the prominent changes in the cortical gray matter across the groups are consistent with recent reports of persistent cortical atrophy in HIV-infected people (Cohen et al. 2010a, b; Thompson et al. 2005) and suggest that the pattern of HIVassociated brain dysfunction in the context of treatment may have evolved from what was previously considered a subcortical disorder (Heaton et al. 1995; Navia et al. 1986a, b) .
Decreases in Glx comprised the largest metabolite change observed across the clinical groups, particularly in the MFC and BG. The Glx peak represents the levels of both glutamine and glutamate and may change in response to events affecting glial and neuronal function (Urenjak et al. 1993) . Recent cross-sectional studies in HIV have found significant decreases in Glx even in NA individuals (Harezlak et al. 2011; Mohamed et al. 2010) . Changes in Glx may thus represent a critical event that occurs prior to the onset of neurocognitive symptoms and may offer a sensitive biomarker of neural health in the early stages of infection. Together with NAA, these metabolites may provide a useful approach to monitoring cerebral function over the course of HIV disease in the era of CART.
The observed declines in Cho, a marker of membrane turnover, were unexpected as was the relative absence of changes in MI, a measure of cellular osmotic changes and glial cell proliferation (Lopez-Villegas et al. 1997; Meyerhoff et al. 1999; Tracey et al. 1996; Urenjak et al. 1993) . In contrast to the findings from cross-sectional studies, this observation suggests these two metabolites can in fact dissociate, possibly as a consequence of the different cellular processes they reflect. Combined, these results suggest a pattern of continuing neural injury in the setting of stable brain inflammation. The reason for this is not presently known, but it is possible that CART may be effective in stabilizing inflammatory responses while other neuroactive events remain unchecked, resulting in membrane damage with loss of cholinecontaining compounds. Quantitative pathological studies are needed to confirm this model. The decrease in creatine, generally considered a marker of energy metabolism, was found only in MFC and BG, suggesting these regions may be particularly vulnerable to global disturbances in metabolic function.
This is the first study to show associations between longitudinal changes in cerebral metabolites and cognitive decline, and expands on a small number of cross-sectional findings (Mohamed et al. 2010; Paul et al. 2007) . Notably, global cognitive decline was associated with decreases in Glx levels in the frontal white matter and the basal ganglia, and marginally with decrease in NAA in the basal ganglia. The Glx finding is particularly noteworthy, as the role of this metabolite in cognitive function has remained uncertain. The current findings also extend a recent study showing significant associations of Glx levels with executive function, working memory, and motor impairments, and together suggest decreases in Glx may contribute importantly to HIV-associated neurocognitive impairment (Mohamed et al. 2010) .
The basis for the current findings is unclear but may be due to the effects of one or more host or disease-related factors. Several studies pre-CART had identified plasma and CSF HIV RNA levels in addition to low current CD4 as important risk factors for neurocognitive impairment (Ellis et al. 1997; McArthur et al. 1997 ). More recently, several groups have reported significant associations between nadir CD4, brain atrophy, and neurocognitive impairment (Cohen et al. 2010b; Heaton et al. 2011 ). However, preliminary findings suggest that mechanisms contributing to progressive brain injury may involve complex relationships among several factors, including HIV viral load, CD4 levels, duration of infection and of treatment, and aging. We have recently shown that the chemokines, MCP-1 and IP10, are associated with decreases in NAA suggesting that markers of immune activation and inflammation contribute to neuropathogenesis ). In addition, underlying comorbid disorders such as hepatitis C, diabetes mellitus, obesity, possibly mediated through one or more inflammatory factors, may also affect risk (Valcour et al. 2004 (Valcour et al. , 2005 van Gorp and Hinkin 2005) . Further studies are needed to disentangle the effects of these factors and their relationships to varying patterns of brain injury.
Results from the current study indicate that progressive brain injury continues to occur in medically stable HIVinfected persons on effective antiretroviral therapies, and these changes are related to declines in cognitive function over time. These results further support MRS as a sensitive measure of HIV-associated brain injury even in neurocognitively asymptomatic individuals and points to its potential value, in combination with cognitive assessments, in monitoring disease progression and response to treatment. These findings suggest that careful monitoring of neurological function in HIVinfected persons is warranted in the setting of chronic disease and treatment.
